National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology

Am J Geriatr Psychiatry. Fall 2001;9(4):346-60.

Abstract

The authors describe the development of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) protocol for Alzheimer disease (AD), a trial developed in collaboration with the National Institute of Mental Health (NIMH), assessing the effectiveness of atypical antipsychotics for psychosis and agitation occurring in AD outpatients. They provide an overview of the methodology utilized in the trial as well as the clinical-outcomes and effectiveness measures that were implemented.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Algorithms
  • Alzheimer Disease / economics
  • Alzheimer Disease / psychology*
  • Antipsychotic Agents / administration & dosage
  • Antipsychotic Agents / economics
  • Antipsychotic Agents / therapeutic use*
  • Benzodiazepines
  • Citalopram / administration & dosage
  • Citalopram / economics
  • Citalopram / therapeutic use*
  • Cost-Benefit Analysis
  • Humans
  • Olanzapine
  • Patient Compliance
  • Pirenzepine / administration & dosage
  • Pirenzepine / analogs & derivatives*
  • Pirenzepine / economics
  • Pirenzepine / therapeutic use*
  • Psychomotor Agitation / drug therapy*
  • Psychomotor Agitation / economics
  • Psychomotor Agitation / etiology*
  • Psychotic Disorders / drug therapy*
  • Psychotic Disorders / economics
  • Psychotic Disorders / etiology*
  • Risperidone / administration & dosage
  • Risperidone / economics
  • Risperidone / therapeutic use*
  • Treatment Outcome

Substances

  • Antipsychotic Agents
  • Citalopram
  • Benzodiazepines
  • Pirenzepine
  • Risperidone
  • Olanzapine